



**Panacea Biotec**  
*Innovation in support of life*

10<sup>th</sup> December, 2019

The Manager, Listing Department  
National Stock Exchange of India Ltd.  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051

BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400 001

NSE Symbol: PANACEABIO

BSE Scrip Code: 531349

**Re.: Press Release – Panacea Biotec announces launch of ViLACT for treatment of Uncontrolled Type 2 Diabetes Mellitus patients**

Dear Sir,

Panacea Biotec Ltd. is pleased to announce the launch of ViLACT, available in four formulations (ViLACT, ViLACT M500, ViLACT M850 and ViLACT M1000), for treatment of Uncontrolled Type 2 Diabetes Mellitus patients.

A copy of the Press Release being issued to the media, etc. in this regard is enclosed for your kind reference and record please.

Kindly acknowledge the receipt.

Thanking you,

Sincerely yours,

for **Panacea Biotec Ltd.**

**Vinod Goel**

**Group CFO and Head Legal  
& Company Secretary**



Encl. As Above

B1 Extn. /G3, Mohan Co-op Indl. Estate,  
Mathura Road, New Delhi -110044  
Email: vinodgoel@panaceabiotec.com  
Phone: D.I.D. +91-11-4167 9015  
Fax: +91-11-4167 9070

**Panacea Biotec Ltd.**

CIN: L33117PB1984PLC022350

Registered Office: Ambala-Chandigarh Highway, Lalru - 140 501, Punjab, India. Ph.: +91-1762-505900, Fax: +91-1762-505906.  
e-mail: corporate@panaceabiotec.com website: www.panaceabiotec.com



**Panacea Biotec**

*Innovation in support of life*




New Delhi, 10<sup>th</sup> December 2019

**Panacea Biotec announces launch of ViLACT for treatment of Uncontrolled Type 2 Diabetes Mellitus patients**

Panacea Biotec is pleased to announce launch of brand ViLACT in India. ViLACT is used in the treatment of Uncontrolled Type 2 Diabetes Mellitus patients with HbA1c >6.5%.

**ViLACT is available in four formulations:**

1. ViLACT : Vildagliptin 50 mg Tablet.
2. ViLACT M 500 : Vildagliptin 50 mg + Metformin HCL 500 mg Tablet.
3. ViLACT M 850 : Vildagliptin 50 mg + Metformin HCL 850 mg Tablet.
4. ViLACT M 1000 : Vildagliptin 50 mg + Metformin HCL 1000 mg Tablet.



*Pd Karan*

CIN: L33117PB1984PLC022350

Corp Office: B-1 Extn. / A-27, Mohan Co-op. Indl. Estate, Mathura Road, New Delhi 110044, India;

Tel: +91 11 41679000, Extn. 1406; DID: +91 11 41578080, Fax: +91 11 41578002;

Mobile: +91 9312693040; Email: [pdkaran@panaceabiotec.com](mailto:pdkaran@panaceabiotec.com); Web: [www.panaceabiotec.com](http://www.panaceabiotec.com)



The total market size of this molecule and its combination is **INR 969 Crore as per AIOCD MAT October '2019** and is growing at the rate of 4%. Vildagliptin product patent (IN 212815) in India has expired on 09<sup>th</sup> December '2019. Vildagliptin is a new oral antidiabetic agent that enhances pancreatic islet cell responsiveness to glucose, is an incretin enhancer, a potent and selective inhibitor of dipeptidyl peptidase-4 (DPP-4), the enzyme responsible for the rapid degradation of the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP). This activity increases levels of active incretins and enhances pancreatic islet  $\alpha$ - and  $\beta$ -cell responsiveness to glucose, thus improving insulin secretion and reducing inappropriate glucagon production, improving insulin sensitivity, improving postprandial lipid and lipoprotein metabolism, and reducing fasting and prandial glucose and HbA1c.

**Speaking on the occasion Dr. Rajesh Jain, Managing Director said:**

“Diacar Strategic Business Unit (SBU) has launched ViLACT brand family. This will open up a new segment for accelerated growth of the SBU.

I am pleased to share that during pre-launch activity that started in the month of October '2019, an innovative campaign was launched to protect our environment wherein 10,000 Doctors from all over India participated by pledging I “ViL ACT” to save the environment by planting over 10,000 plants, saying NO to plastic using Khadi bags, in the process giving boost to MSME sector as part of promoting use of Khadi.


In New Year 2020, our aim is to reach 100,000 Doctors and plant over 100,000 saplings and we have created a website [www.vilact.panaceabiotec.com](http://www.vilact.panaceabiotec.com) on this occasion.



Mr. Susheel Umesh, Chief Executive, Domestic Formulation said *the* ViLACT brand will be an affordable, high quality medicine in the armamentarium of a physician treating patients with Diabetes. The patients have always been and will continue to be the center of our business. The Physician needs a lot of options to bring down the burden of Diabetes and we with the ViLACT range will continue to support the patient and physician in this journey.”



CIN: L33117PB1984PLC022350

Corp Office: B-1 Extn. / A-27, Mohan Co-op. Indl. Estate, Mathura Road, New Delhi 110044, India;  
Tel: +91 11 41679000, Extn. 1406; DID: +91 11 41578080, Fax: +91 11 41578002;  
Mobile: +91 9312693040; Email: [pdkaran@panaceabiotec.com](mailto:pdkaran@panaceabiotec.com) ; Web: [www.panaceabiotec.com](http://www.panaceabiotec.com)





## About Panacea Biotech

Panacea Biotech is a leading pharmaceutical and biotechnology company with established Research, Manufacturing and Marketing capabilities. The Company is amongst the top 15 pharmaceutical companies in its represented market in India and amongst top 60 pharmaceutical Companies in India (AIOCD AWACS-MAT MAR-2019). The Company has been awarded with the prestigious "India Innovation Award – Top 50" by Clarivate Analytics (Thomson Reuters) for the years 2015 & 2016.

The product portfolio includes innovative products in therapeutic areas of organ transplantation, nephrology, diabetes, osteoporosis, cardiovascular diseases, vaccines, and oncology. The Company is working on a robust pipeline of high barrier to entry generics products, thus leveraging its capabilities in the areas of nanotechnology and platform drug delivery technologies like micro-particles, liposomes, gastro-retentive systems.

*Scorion*

CIN: L33117PB1984PLC022350

Corp Office: B-1 Extn. / A-27, Mohan Co-op. Indl. Estate, Mathura Road, New Delhi 110044, India;

Tel: +91 11 41679000, Extn. 1406; DID: +91 11 41578080, Fax: +91 11 41578002;


Mobile: +91 9312693040; Email: [pdkaran@panaceabiotec.com](mailto:pdkaran@panaceabiotec.com) ; Web: [www.panaceabiotec.com](http://www.panaceabiotec.com)



It has introduced its products in around 30 countries across the world, including USA, Germany and Russian Federation, through a combination of strategic collaborations and direct presence in select geographies. The Company has research collaborations with leading national and international research organizations and corporations. The company has around 2750 employees.

**For more information, please contact:**

<b>For Investors:</b>	<b>For Media:</b>
Mr. Devender Gupta Chief Financial Officer and Head Information Technology Tel: + 91-11-4167900 Ext.1225 41578011 (Direct) Mobile : + 91 98109 04102 Email: devendergupta@panaceabiotec.com	Mr. P.D. Karan Vice President Corporate Communication & Business Development Tel: + 91-11-4167900 Ext.1406 41578080 (Direct) Mobile : + 91 9810500539/9312693040 Email: pdkaran@panaceabiotec.com



CIN: L33117PB1984PLC022350

Corp Office: B-1 Extn. / A-27, Mohan Co-op. Indl. Estate, Mathura Road, New Delhi 110044, India;  
Tel: +91 11 41679000, Extn. 1406; DID: +91 11 41578080, Fax: +91 11 41578002;  
Mobile: +91 9312693040; Email: [pdkaran@panaceabiotec.com](mailto:pdkaran@panaceabiotec.com) ; Web: [www.panaceabiotec.com](http://www.panaceabiotec.com)